Page last updated: 2024-12-08

batabulin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

batabulin: disrupts microtubule polymerization by binding certain beta-tubulin isotypes; effective against some multidrug-resistant tumors; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID216324
CHEMBL ID79280
SCHEMBL ID18845
MeSH IDM0305635

Synonyms (33)

Synonym
t-138067
tl 057
batabulin
CHEMBL79280
T67 ,
tl-057
t138067
t-67
t4np8g3k6q ,
batabulin [usan]
benzenesulfonamide, 2,3,4,5,6-pentafluoro-n-(3-fluoro-4-methoxyphenyl)-
2-fluoro-1-methoxy-4-pentafluorophenylsulfonamidobenzene
unii-t4np8g3k6q
D06560
195533-53-0
batabulin (usan/inn)
t 138067
2,3,4,5,6-pentafluoro-n-(3-fluoro-4-methoxyphenyl)benzenesulfonamide
n-(3-fluoro-4-methoxyphenyl)-2,3,4,5,6-pentafluorobenzenesulfonamide
batabulin [inn]
tl057
batabulin [who-dd]
SCHEMBL18845
DTXSID70173230
HY-13563
Q27289662
CS-0007170
MS-25971
195533-53-0 (free)
t138067t138067
STARBLD0000893
Z1478321775
AKOS040732531
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID222454Inhibition of growth of human mammary carcinoma (MCF-7) cell line that exhibits the MDR phenotype.2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier.
AID53918Tested for caspase activation activity in colorectal DLD-1 cell line2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Discovery of substituted N-phenyl nicotinamides as potent inducers of apoptosis using a cell- and caspase-based high throughput screening assay.
AID222325Inhibition of growth of human mammary carcinoma (MCF-7) cell line.2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier.
AID1382713Antiproliferative activity against human BEAS2B cells after 70 hrs by alamar blue assay2018European journal of medicinal chemistry, Mar-25, Volume: 148Enediynes bearing polyfluoroaryl sulfoxide as new antiproliferative agents with dual targeting of microtubules and DNA.
AID27920Calculated partition coefficient (clogP)2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier.
AID1382719Antiproliferative activity against HUVEC after 70 hrs by alamar blue assay2018European journal of medicinal chemistry, Mar-25, Volume: 148Enediynes bearing polyfluoroaryl sulfoxide as new antiproliferative agents with dual targeting of microtubules and DNA.
AID1382714Cytotoxicity against human BEAS2B cells assessed as reduction in cell viability after 70 hrs by alamar blue assay2018European journal of medicinal chemistry, Mar-25, Volume: 148Enediynes bearing polyfluoroaryl sulfoxide as new antiproliferative agents with dual targeting of microtubules and DNA.
AID1382720Cytotoxicity against HUVEC assessed as reduction in cell viability after 70 hrs by alamar blue assay2018European journal of medicinal chemistry, Mar-25, Volume: 148Enediynes bearing polyfluoroaryl sulfoxide as new antiproliferative agents with dual targeting of microtubules and DNA.
AID1382718Ratio of IC50 for antiproliferative activity against human HBL100 cells to IC50 for cytotoxicity against human HBL100 cells2018European journal of medicinal chemistry, Mar-25, Volume: 148Enediynes bearing polyfluoroaryl sulfoxide as new antiproliferative agents with dual targeting of microtubules and DNA.
AID1382725Disruption of microtubule network in human A498 cells at 5 times antiproliferative IC50 after 1 to 12 hrs by immunofluorescence assay2018European journal of medicinal chemistry, Mar-25, Volume: 148Enediynes bearing polyfluoroaryl sulfoxide as new antiproliferative agents with dual targeting of microtubules and DNA.
AID1382715Ratio of IC50 for antiproliferative activity against human BEAS2B cells to IC50 for cytotoxicity against human BEAS2B cells2018European journal of medicinal chemistry, Mar-25, Volume: 148Enediynes bearing polyfluoroaryl sulfoxide as new antiproliferative agents with dual targeting of microtubules and DNA.
AID1382722Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay2018European journal of medicinal chemistry, Mar-25, Volume: 148Enediynes bearing polyfluoroaryl sulfoxide as new antiproliferative agents with dual targeting of microtubules and DNA.
AID1382717Cytotoxicity against human HBL100 cells assessed as reduction in cell viability after 70 hrs by alamar blue assay2018European journal of medicinal chemistry, Mar-25, Volume: 148Enediynes bearing polyfluoroaryl sulfoxide as new antiproliferative agents with dual targeting of microtubules and DNA.
AID208695Tested for caspase activation activity in human breast cancer T47D cells2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Discovery of substituted N-phenyl nicotinamides as potent inducers of apoptosis using a cell- and caspase-based high throughput screening assay.
AID43315Concentration in brain of CD-1 mice exposed for 5 min to 30-40 mg/kg via bolus injection2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier.
AID1382723Ratio of IC50 for antiproliferative activity against human MIAPaCa2 cells to IC50 for cytotoxicity against human MIAPaCa2 cells2018European journal of medicinal chemistry, Mar-25, Volume: 148Enediynes bearing polyfluoroaryl sulfoxide as new antiproliferative agents with dual targeting of microtubules and DNA.
AID1382721Ratio of IC50 for antiproliferative activity against HUVEC to IC50 for cytotoxicity against HUVEC2018European journal of medicinal chemistry, Mar-25, Volume: 148Enediynes bearing polyfluoroaryl sulfoxide as new antiproliferative agents with dual targeting of microtubules and DNA.
AID1382716Antiproliferative activity against human HBL100 cells after 70 hrs by alamar blue assay2018European journal of medicinal chemistry, Mar-25, Volume: 148Enediynes bearing polyfluoroaryl sulfoxide as new antiproliferative agents with dual targeting of microtubules and DNA.
AID222132Inhibition of growth of human cervical carcinoma (HeLa) cell line.2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier.
AID160008Concentration in plasma of CD-1 mice exposed for 5 min to 30-40 mg/kg via bolus injection2001Journal of medicinal chemistry, Oct-25, Volume: 44, Issue:22
Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier.
AID220415Tested for caspase activation activity in human breast cancer ZR-75-1 cells2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Discovery of substituted N-phenyl nicotinamides as potent inducers of apoptosis using a cell- and caspase-based high throughput screening assay.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (10.00)18.2507
2000's6 (60.00)29.6817
2010's3 (30.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.38 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (20.00%)5.53%
Reviews2 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (60.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]